While PD-L1 is a viable target and predictive marker in non-small cell lung cancer, its inhibitors have shown limited efficacy in small cell lung cancer, and the PD-L1-status is not predictive of the ICI response in SCLC, indicating that these tumors might be associated with different immune microenvironments [72]. This evidence concerns the gene CD274 and small cell lung carcinoma.